Filing Flows › Seres Therapeutics (MCRB) › Q4 2025
Seres Therapeutics (MCRB) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 12, 2026
Seres Therapeutics (MCRB) reported revenue of $438K for the fourth quarter 2025 (Q4 2025) and +25% from the quarter before.
Seres Therapeutics, Q4 2025: revenue $438K, net loss $15.3M, operating cash flow −$14.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $438K | +25% | — |
| Operating profit | −$19.4M | — | — |
| Net earnings | −$15.3M | -287% | — |
| Operating cash flow | −$14.7M | -767% | — |
What changed
Revenue was $438K in Q4 2025, up 25% from the previous quarter.
Operating costs exceeded revenue by $19.4M, an operating margin of -4424.0%. The quarter ended with a net loss of $15.3M, after a profit of $8.2M the previous quarter. Non-operating items added $4.0M, -26% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$14.7M. Non-cash charges added back $1.0M of depreciation and amortization and $3.2M of share-based compensation. Working capital and other items used $3.5M. Capital expenditures of $29K exceeded it, leaving free cash flow of −$14.7M.
Questions
What was Seres Therapeutics' revenue in the fourth quarter 2025?
Seres Therapeutics (MCRB) reported revenue of $438K for the fourth quarter 2025 (Q4 2025) and +25% from the quarter before.
Source: Seres Therapeutics 10-K on SEC EDGAR.